Chelation Therapy

The ten top killers of Americans (in the order of frequency) include heart disease, cancer, stroke, accidents, pneumonia, diabetes, cirrhosis, arteriosclerosis, suicides, and infant death. All but accidents, pneumonia, suicides, and infant death have an underlying connection to reduced blood circulation. More than 90 percent of Americans live in jeopardy of having a serious illness relating to the circulatory system. 

The human and financial cost of cardiovascular disease in the U.S. is astronomical. Every year, approximately 1.5 million Americans have a heart attack, 300,000 of whom die before receiving medical attention. The treatment of cardiovascular disease rings up a total of $100 billion dollars annually-$200,000 spent every minute. Coronary artery bypass surgery (bypassing the blocked heart artery with grafted leg artery, average cost $44,000) is the most frequently prescribed surgical procedure for heart disease, costing $10 billion per year. Numerous leading medical doctors and authorities have stated that coronary bypass surgery is over prescribed and often unnecessary. Nearly 20,000 people die every year as a result of bypass surgery or angioplasty (ballooning of the occluded artery, average cost $21,000). 

Intravenous Chelation is far safer, much less expensive, and less invasive. Proven effective finally in one of the more controversial studies spanning years was the TACT trial. Your tax dollars to the tune of $31 million dollars indeed showed what has been common knowledge for over 50 yes 50 years, Chelation saves lives. It’s been in use for  circulatory disorders for years off label and now its benefits for cardiovascular patients are now even clearer following this study.

The key take away points from analysis of the TACT study :”There was an overall 18% reduction in a composite end point, which included death, heart attack, stroke, coronary revascularization, and hospitalization for angina, but each of these was reduced.” Subgroup analyses also revealed that patients with diabetes and those with an anterior MI also appeared to benefit significantly from chelation therapy, said Topol.(Dr Eric Topol (Scripps Clinic, La Jolla, CA) Interestingly he directed his wrath at researchers who apparently did not use consistent consent forms as a big deal, creating a “controversial study”…..really ?

IV Chelation does pose some risks however, as does any medical procedure.  Although nontoxic, EDTA produces side effects in a very small number of patients. These include burning, redness and swelling at the injection site, fever, hypotension (low blood pressure), joint pain, skin outbreaks or rashes, upset stomach, and, rarely, irritation of the kidneys and liver. These effects are RARELY noted by the patients and generally occur if the IV is poorly placed or the flow rate of the solution is too rapid. There has been a consistent way to calculate the appropriate dose for over 25 years now. We spend a significant amount of time with our patients and monitor them throughout the procedure. Our experience has been very positive with none of the above side effects, after hundreds of IV’s. 
In addition to the effectiveness of IV EDTA Chelation therapy in treating cardiovascular disease and heavy metal toxicity, research has documented its benefits for aneurysm, Alzheimer’s disease and senile dementia, arthritis, autoimmune conditions, cancer, cataracts, diabetes, emphysema, gallbladder stones, hypertension, kidney stones, Lou Gehrig’s disease, osteoporosis, Parkinson’s disease, scleroderma, stroke, varicose veins, venomous snake bite, and other conditions involving an interruption in blood flow and diminished oxygen delivery. 

Some cardiologists who understand the benefits of intravenous EDTA Chelation do not recommend its use with patients who are debilitated, emaciated, have weak or diseased kidneys, or advanced cardiovascular disease (end stage). They believe the sudden, massive infusion of EDTA puts too much stress on the kidneys, liver and detoxification pathways in these patients and could be harmful or even dangerous. Other doctors and medical researchers disagree, contending that “transient kidney malfunction” is a normal physiological adaptation occurring during the passage of toxic products (chelated metals and chemicals) through the kidneys, and that properly administered IV Chelation will not cause kidney damage. My experience has been consistently that by tailoring the proper dose and the flow rate even weak and debilitated patients can be safely treated. 

A common misconception about chelation is that it lowers the levels of calcium in the bones and teeth, as the body draws calcium from them to replace the calcium drawn from the blood by the chelation process. On the contrary, the calcium to restore blood levels is drawn from places in the body where calcium has built up unnaturally, as in arterial plaques (which contribute to clogged arteries), calcified bursae (a source of bursitis), arthritic joints, and kidney stones. 

Further, Garry Gordon, M.D., D.O., co-founder of the American College for Advancement in Medicine (ACAM) and a pioneer in chelation therapy, states, “If calcium levels start to drop, the parathyroid glands kick in and start secreting parathormone which ‘steals’ back enough calcium from the EDTA (and other) chelates to keep the heart beating normally (serum calcium must stay at a constant level for normal heart function) and to activate cells called osteoblasts, which strengthen and rebuild bone. The more chelation we give people, the less osteoporosis they have and the less age-related calcium accumulation

[arterial wall plaques] there is in the blood vessels.” 

There is no limit to the amount of IV EDTA Chelation a person can be given and the peak beneficial effects last up to two months after treatment. IV Chelation is safe for children as well as adults. People over 90 years old have enjoyed the benefits of chelation and more than 200,000 children in the U.S. have undergone IV Chelation as treatment for lead poisoning. 

There has been a large body of scientific information published on chelation therapy. The following list of sites will give you an overview of the literature and some of the opinions of the leading physicians in this field. 


The History of EDTA 

Number of good articles for review of Chelation subjects 

For information regarding the recently completed 31 Million dollar TACT study of chelation therapy, by the National Institute of Health go to :

Want to see who and where the above study started….

 Group Backs New NIH Chelation Therapy Study For Heart Disease

Some of the scientific findings include:
– Stabilization of arterial intracellular membranes and maintenance of the electrical charge of platelets in the blood, reducing blood clumping (aggregation) and preventing blood clots. 

– Marked improvement in nearly 100% of 2,870 studied patients with peripheral vascular disease 

– Normalization of half of treated cardiac arrhythmias 

– Reductions of cerebrovascular occlusion and improved cognitive function in people with memory and concentration deficits and improved visual acuity (when problems are caused by arterial blockage) 

– Improved myocarditis due to lead poisoning. 

– Reduction of blood fat levels and improved capillary blood flow. o Increased peripheral blood flow to the extremities. 

-Improved compliance of vascular tissues; decalcification of elastic tissues resulting in improved elasticity and resilience. 

-Improved red blood cell membrane flexibility and permeability to potassium 

-Decreased blood pressure levels, as a result of excretion of cadmium from renal tissues, diminished peripheral resistance, improved blood vessel resilience and pliability, decreased vascular spasm, and improved magnesium uptake. 

Intravenous Chelation has two drawbacks, however. Although much safer and less expensive than coronary bypass surgery or angioplasty, it is still relatively expensive as no insurance company will reimburse for the procedure ($125.00 dollars per visit) and not widely available, as there are comparatively few experienced physicians certified in IV Chelation therapy. Interestingly after the TACT trials very positive outcomes it still remains non-reimbursable by insurance carriers. No common sense here other than to direct more payments to hospitals and very invasive and high dollar interventions. Sad that preventive medicine remains the odd child out in our system of disease vs health care, even though your mandated to have insurance and prevention is given loads of press …..go figure.

Dr. Kadish is certified and a member on the committee of the American College for Advancement in Medicine, (ACAM) involved in the board certification process for chelation therapy and has been certified since 2003. 

At the Center, we have non-invasive testing methods to evaluate your progress in addition to the subjective feelings of well being that many of the patients experience. Our expanded cardiovascular evaluation panels and equipment will give you an unequivocal means of measuring your vascular systems integrity. 

A healthy heart is a happy heart….